[1] Yurdaydin C, Li Y, Ha JH, et al. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther, 1995,273:185-192.
[2] 施海东. 门冬氨酸鸟氨酸联合纳洛酮注射液治疗肝性脑病的疗效观察. 中国现代药物应用,2010,4:117-118.
[3] 周泽文,钟晓妮,周宝勇,等. 门冬氨酸鸟氨酸联合纳洛酮对肝性脑病患者认知功能和预后及其神经肽类水平的影响. 中华肝脏病杂志,2013,21:385-388.
[4] Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion, 2006,73:86-93.
[5] Lv XF, Qiu YW, Tian JZ, et al. Abnormal regional homogeneity of resting-state brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy.Liver Int, 2013,33:375-383.
[6] Kamel L, Saleh A, Morsy A, et al. Plasma met-enkephalin, b-endorphin and leuenkephalin levels in human hepatic encephalopathy. J East M editerr Health, 2007,13: 257-265.
[7] Jiang Q, Jiang G, Welty TE, et al. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther, 2010,35: 333-341. |
